Clinical pharmacology of anti-il-17 receptor antibody khk4827 (brodalumab) in Japanese healthy volunteers and subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled study

被引：0
|
作者：
Nemoto, O. [1 ]
Nagashima, H. [2 ]
Sayama, K. [3 ]
Kobayashi, H. [4 ]
机构：
[1] Sapporo Skin Clin, Sapporo, Hokkaido, Japan
[2] Yanagibashi Hosp, Yanagibashi Clin Trial Ctr, Tokyo, Japan
[3] Ehime Univ, Grad Sch Med, Dept Dermatol, Matsuyama, Ehime 790, Japan
[4] Med Corp Shinanokai, Shinanozaka Clin, Tokyo, Japan
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2013年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P049
引用
收藏
页码：21 / 22
页数：2
相关论文
共 50 条
  • [21] Pharmacokinetics and safety of PC-SOD, a lecithinized recombinant superoxide dismutase, in healthy Chinese subjects: A phase 1, randomized, placebo-controlled, dose-escalation study
    Chen, Rui
    Zhao, Qian
    Wu, Ni
    Zhong, Wen
    Jin, Xin
    Liu, Chunyan
    Zhu, Zhenyu
    Hu, Pei
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2019, 57 (12) : 596 - 602
  • [22] Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study of GB223, a Fully-Humanized Monoclonal Antibody to RANKL, in Healthy Chinese Adults
    Li, Chen
    Liu, Haiyan
    Liao, Yixiang
    Zhu, Yu
    Tian, Jingyuan
    Wang, Xuan
    Hu, Zhiqin
    Zhan, Yaoxuan
    Li, Xianbo
    Liang, Xintong
    He, Jin
    Li, Yongmei
    Shang, Dewei
    Zheng, Qingshan
    Wang, Tenghua
    Song, Haifeng
    Fang, Yi
    BIODRUGS, 2023, 37 (05) : 721 - 735
  • [23] Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study of GB223, a Fully-Humanized Monoclonal Antibody to RANKL, in Healthy Chinese Adults
    Chen Li
    Haiyan Liu
    Yixiang Liao
    Yu Zhu
    Jingyuan Tian
    Xuan Wang
    Zhiqin Hu
    Yaoxuan Zhan
    Xianbo Li
    Xintong Liang
    Jin He
    Yongmei Li
    Dewei Shang
    Qingshan Zheng
    Tenghua Wang
    Haifeng Song
    Yi Fang
    BioDrugs, 2023, 37 : 721 - 735
  • [24] The Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Ebronucimab in Healthy Volunteers: Result From a Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Dose-Escalation Study
    Chen, Rui
    Tian, Zhuang
    Tang, Xiange
    Hu, Pei
    Wang, Lvya
    Xia, Yu
    Li, Baiyong
    Wang, Max
    Ni, Xiang
    Wang, Guoqin
    Zhang, Shuyang
    CIRCULATION, 2022, 146
  • [25] Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study
    Jiang, Congjun
    Zhou, Huan
    Zhang, Wanlu
    Xia, Yu
    Li, Baiyong
    Ni, Xiang
    Wang, Guoqin
    Zhang, Wenhui
    Chen, Benchao
    He, Zhimei
    Zhang, Min
    Chen, Rui
    Jin, Hongzhong
    Deng, Liehua
    DERMATOLOGY AND THERAPY, 2023, 13 (02) : 555 - 567
  • [26] Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study
    Congjun Jiang
    Huan Zhou
    Wanlu Zhang
    Yu Xia
    Baiyong Li
    Xiang Ni
    Guoqin Wang
    Wenhui Zhang
    Benchao Chen
    Zhimei He
    Min Zhang
    Rui Chen
    Hongzhong Jin
    Liehua Deng
    Dermatology and Therapy, 2023, 13 : 555 - 567
  • [27] Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study
    Irie, S.
    Matsumura, Y.
    Zdravkovic, M.
    Jacobsen, L. V.
    Kageyama, S.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2008, 46 (06) : 273 - 279
  • [28] Phase I, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of NI-0401 (a Fully Human Anti-CD3 Monoclonal Antibody) in Patients with Moderate to Severe Active Crohn's Disease
    van der Woude, C. Janneke
    Stokkers, Pieter
    Van Bodegraven, Ad A.
    Van Assche, Gert
    Hebzda, Zbigniew
    Paradowski, Leszek
    D'Haens, Geert
    Ghosh, Subrata
    Feagan, Brian
    Rutgeerts, Paul
    Dijkstra, Gerard
    de Jong, Dirk J.
    Oldenburg, Bas
    Farhan, Mahdi
    Richard, Tristan
    Dean, Yann
    Hommes, Daniel W.
    INFLAMMATORY BOWEL DISEASES, 2010, 16 (10) : 1708 - 1716
  • [29] Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: Results of a pilot, multicenter, multiple-dose, placebo-controlled study
    Gottlieb, AB
    Lebwohl, M
    Shirin, S
    Sherr, A
    Gilleaudeau, P
    Singer, G
    Solodkina, G
    Grossman, R
    Gisoldi, E
    Phillips, S
    Neisler, M
    Krueger, JG
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 43 (04) : 595 - 604
  • [30] Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study
    Yang, Ling
    Fang, Yuan
    Luo, Yuan
    Fu, Meng
    Shen, Kai
    Luo, Zhu
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024, 33 (07) : 741 - 752
12345